

Apolipoprotein E genotype and MRI-detected brain alterations pertaining to neurodegeneration: A systematic review

Albert Dayor Piersson^{a,b}, Mazlyfarina Mohamad^{a,*}, Subapriya Suppiah^c, Nor Fadilah Rajab^d

^aDiagnostic Imaging and Radiotherapy Programme, Universiti Kebangsaan Malaysia, 50300 Kuala Lumpur, Malaysia. Email: P97002@ukm.edu.my

^bDepartment of Imaging Technology & Sonography, School of Allied Health Sciences, University of Cape Coast, University Post Office, Cape Coast, Ghana. Email: albert.piersson@ucc.edu.gh; albert.piersson@gmail.com

^cCentre for Diagnostic Nuclear Imaging, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia. Email: subapriya@upm.edu.my

^dBiomedical Science Programme, Center for Healthy Aging and Wellness, Universiti Kebangsaan Malaysia, 50300 Kuala Lumpur, Malaysia. Email: nfadilah@ukm.edu.my

*Correspondence: Diagnostic Imaging and Radiotherapy Programme, Universiti Kebangsaan Malaysia, 50300 Kuala Lumpur, Malaysia. Email: mazlyfarina@ukm.edu.my

Manuscript Word Count: 4,994

Abstract Word Count: 250

Article Type: Systematic Review

Abstract

Introduction

The effect of apolipoprotein E (APOE) genotype, particularly APOE ϵ 4, the main genetic risk factor for late-onset Alzheimer's disease (LOAD), has been widely explored in neuroimaging studies pertaining to older adults. The goal of this systematic review was to review the literature on the relationship between carriage of the APOE ϵ 4 allele and grey matter (GM) changes across various age groups and its influence on neurodegeneration as evidenced by structural magnetic resonance imaging (MRI).

Methods

A search of the electronic databases Pubmed, Scopus, Ovid and Cochrane was carried out till March 2020. Only studies published in English were included. Risk of bias of each study was assessed using the modified Newcastle-Ottawa Scale.

Results

A total of 115 articles met the inclusion criteria. Methodological quality varied from poor to good. There is moderate evidence of reduced GM volume in the middle frontal gyrus, precuneus, hippocampus, hippocampal subfields, amygdala, parahippocampal gyrus, middle temporal lobe, whole temporal lobe, temporal pole, and posterior cingulate cortex in APOE ϵ 4 carriers.

Conclusion

The present data supports the utility of the hippocampal GM volume to evaluate early structural neurodegenerative changes that occurs in APOE ϵ 4 positive elderly individuals who are at increased risk of developing LOAD. Furthermore, the evidence supports serial measurements and comparison of hippocampal volume based on age group, to track the progression of neurodegeneration in APOE ϵ 4 carriers. Additional longitudinal studies are necessary to confirm whether the combination of MRI-detected hippocampal atrophy with APOE ϵ 4 carrier status, can better predict the development of LOAD in cognitively normal individuals.

Keywords: apolipoprotein; magnetic resonance imaging; Alzheimer's disease; Dementia

1. Introduction

Alzheimer's disease (AD) is the commonest type of dementia and it is postulated to cause 60–80% of cases worldwide (WHO, 2020; Alzheimer's Association [AA], 2020). While older age group is recognized as the greatest risk factor for AD (AA, 2020; Rivan et al., 2020; Ibrahim et al., 2019), there are multiple other factors that are responsible for cognitive decline (Hussin et al., 2019; Lee et al., 2012; Shahar et al., 2013; Meramat et al., 2015). One of the most important non-modifiable risk factors is the apolipoprotein E (APOE) genotype which has been implicated in late-onset Alzheimer's disease (LOAD). APOE is a 34 kDa glycoprotein containing 299 amino acid residues (Utermann, 1975) which functions as an essential constituent of plasma lipoproteins. APOE ϵ 2 is a less common isoform and is considered protective against the development of AD (Wu and Zhao, 2016). Conversely, some studies postulate that ϵ 2 may also be an important risk factor for AD (Kaur et al., 2005; van Duijn et al., 1995). The APOE ϵ 3 allele is the most common genotype in the general population and apparently does not affect the risk of AD (Qiu et al., 2019). Universally, the APOE ϵ 4 allele is the strongest identified genetic risk factor for both LOAD (Corder et al., 1993; Strittmatter et al., 1993) and sporadic AD (Poirier et al., 1993). APOE ϵ 4 is usually present in 13.7% of worldwide population, but its frequency in LOAD patients is drastically increased to 40% (Farrer et al. 1997).

The pathological hallmarks underlying AD include A β plaques and neurofibrillary tangles (NFTs), and abnormal tau protein concentrations in the central nervous system (Sperling et al., 2011). Biomarkers indicating brain A β depositions are typically demonstrated as decreased levels of cerebrospinal fluid (CSF) A β 42 and increased retention of amyloid tracer on positron emission tomography (PET) (Sperling et al., 2011; Suppiah et al., 2019). Structural magnetic resonance imaging (MRI) changes are also used as neurodegeneration biomarkers of AD, and known to manifest later compared to changes demonstrated on PET (Sperling et al., 2011). This suggests that the role of measuring structural changes may be limited in its ability to detect early changes in AD, prior to symptoms becoming apparent. A novel approach is to investigate the presence of APOE ϵ 4 and combine the outcome with brain MRI detected changes in those who are at a higher risk of developing AD by the virtue of their age, family history, or other related risk factors. This can lead to improved diagnostic accuracy and better prediction of future clinical outcome with regards to LOAD. This stems from the compelling body of evidence that point to the crucial role of APOE ϵ 4 in modulating cerebral A β and tau protein levels (Castellano et al., 2011; Strittmatter et al., 1994), neuronal activity (Sheline et al., 2010; Zhu et al., 2018), and ultimately gray matter volume (GMv) (Cacciaglia et al., 2018). Indeed previous systematic reviews and meta-analyses have explored the association between the APOE ϵ 4 allele and brain

structural changes; however these studies have only focused on selected regions of the brain, particularly the temporal lobe structures, with essentially no details on the subcortical regions (Liu et al., 2015; Cherbuin et al., 2007). Furthermore, these studies have placed a cap on the age group of the subjects when selecting their sample population as a criterion for inclusion or exclusion of subjects, effectively excluding younger age from adult groups. Therefore, this systematic review summarizes current available evidence on (1) the significant cortical and subcortical MRI-detected brain changes in neurodegeneration, (2) the relationship between the presence of APOE ϵ 4 allele and the changes that occur in the cortical and subcortical brain structures, and (3) the association between APOE ϵ 4 and cortical and subcortical changes examined with brain MRI across all age groups.

2. Material and methods

2.1 Sources of information and search approach

The following electronic databases were initially searched till August 19, 2019: Pubmed (<http://www.ncbi.nlm.nih.gov/pubmed/>), Scopus (<https://www.scopus.com/home.uri>), Ovid (<http://www.ovid.com/site/index.jsp>), and Cochrane (<https://www.cochranelibrary.com/search>). The search was updated on 3rd March, 2020. Further, a review of included studies in the systematic review undertaken by Cherbuin et al. (2007) was conducted. The search was further complemented with a search of the grey literature. Additionally, cross referencing of all the bibliography of the primary sourced eligible articles was undertaken to identify the articles that fulfilled the inclusion criteria. The search method was in accordance with the Patient, measurement Instrument, Comparison, Outcome (PICO)-framework. The following search terms were entered: (“Apolipoprotein” OR “APOE”) AND (“brain imaging” OR “magnetic resonance imaging” OR “MRI”) AND (“Temporal lobe” OR “Hippocampus” OR “Medial Temporal Lobe” OR “Parahippocampal gyrus” OR “Amygdala” OR “Entorhinal cortex” OR “Parietal lobe” OR “Frontal lobe” OR “Occipital lobe” OR “Precuneus” OR “Entorhinal cortex” OR “Atrophy”) AND (“Brain size” OR “ Brain volume” OR “Gray matter volume” OR “Cortical Thickness”).

2.2 Study selection

The articles had to fulfil the following inclusion criteria adopted from Cherbuin et al. (2007): (1) human subjects; (2) healthy subjects and/ or subjects with AD or dementia (including vascular dementia [VaD], dementia with Lewy bodies [DLB] and frontotemporal dementia [FTD]); (4) all subjects were examined using structural brain MRI technique; (5) brain regions were investigated for whole or regional alterations, and measurements made pertaining to GM

thickness and/or GMv; (6) articles published in English language, and (7) full-text available articles. Articles that did not meet each of the listed criteria were excluded.

2.3 Eligibility Criteria

Assessment for eligibility was undertaken by conducting a screening of all articles obtained in accordance with the listed inclusion and exclusion criteria. Assessment for eligibility was undertaken by A.D.P. A.D.P is a PhD candidate working on 'neuroimaging' of MCI/AD patients. After identifying potentially eligible articles, duplicates were removed, and the first phase of the screening was performed based on title and abstract. When an abstract is deemed to provide inadequate information, a retrieval of the whole text was undertaken. The next phase involved the retrieval of full text articles which were evaluated to ensure that they meet the inclusion criteria. Consensus was often reached when there is concern regarding the inclusion or exclusion of an article.

2.4 Data information

The following information were extracted from each included article and presented in Tables 1 and 2. In Table 1, the following items are listed: (1) authors, (2) magnetic fields, (3) MRI parameters, (4) pulse sequences, (5) measurement and analysis method. Table 2 shows (1) authors, (2) age and gender of patient group, (3) age and gender of the control group, (4) main findings, and (5) remarks.

2.5 Risk of bias in individual studies

In order to determine the methodological quality of each eligible study, the Newcastle–Ottawa Scale (NOS, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp) designed purposely for case–control and cohort studies was used (Table 3). The NOS is apportioned into three categories: selection, comparability, and exposure/outcome. The maximum score on the NOS is nine points, which represents the highest methodological quality. To avoid bias, two reviewers (A.D.P. and M.M) independently conducted the methodological quality assessment. After quality assessment, comparison was made and consensus was reached when differences occurred in the scores. One point is awarded for each item under the Selection and Exposure/Outcome categories, while two points are awarded for the Comparability category. Regarding the response rate, a subcategory under Exposure, this was replaced because it did not fit the assessment criteria for the study. Therefore, this subcategory was replaced with item 9 to assess for 'MRI data quality' (Coppieters et al., 2016). This was to check whether

researchers did perform visual inspection of 'MRI data quality'. Overall, the maximum achievable score of a study was 9 based after modifying the NOS, which represented the test methodological quality. The NOS Scale is described in Table 3 as a footnote.

Regarding the study design and methodological quality, a level of evidence (LOE) was assigned to each study, in accordance with the 2005 classification system of the Dutch Institute for Healthcare Improvement (CBO) (http://www.cbo.nl/Downloads/632/bijlage_A.pdf) (Table 4). Following the clustering of studies with comparable methods or results, the strength of conclusion was determined (Table 5) based on the CBO classification, which accounted for the study designs as well as the risk of bias.

3.0 Results

3.1 Study Selection

The study selection process of studies that met the inclusion criteria is shown in Figure 1. Briefly, the initial search yielded a total of 800 studies. After eliminating duplicates, 475 studies remained. Further exclusion of studies based on titles and abstracts led to 239 articles remaining. After assessing the full-text articles, a total of 124 articles were removed, leaving total of 26 studies 115 which were included in the current study (Figure 1).

3.2 Study Characteristics

Briefly, from Table 1, for the studies that documented the MRI parameters, the magnetic field strengths ranged between 0.22 T to 7.0 T, repetition time (TR) and echo time (TE) varied between 2.73 to 10,000 ms and 2.0 to 30,153 ms respectively. Other parameters such as FA and ST varied between 7^0 to 15^0 and 1 to 10 mm respectively. While most studies acquired 3D T₁-weighted imaging using gradient echo pulse sequence, a few studies acquired T₂-weighted imaging (Barboriak et al., 2000; Doody et al., 2000; Kerchner et al., 2014; Mueller and Weiner (2009); Mueller et al., 2008; Donix et al., 2013). Even though most studies used volumetric measures for analysis on semi- or fully automated software, a small number of studies used manual tracing (Du et al., 2000; Tanaka et al., 1998; Geroldi et al., 2000; Geroldi et al., 1999; Lu et al., 2011; Juottonen et al., 1998; Barzokis et al., 2006), and visual analysis (Cotta Ramusino et al., 2019; Barber et al., 1999; Doody et al., 2000).

3.3 Risk of bias and level of evidence

Table 3 shows the results of the methodological quality assessment. The LOE is graded as follows: -, score not fulfilled; +, score fulfilled; /, answer is unclear. Methodological quality varied from poor to good, between 3 of 9 and 8 of 9. Most studies lost points on 'selection of controls', and 'definition of controls', and 'MRI data quality'. This was mainly because authors did not provide the required information or the information was inadequate. Most eligible studies matched participants for age and gender. A few studies controlled for additional factors (e.g. APOE ε4).

In addition, Table 2 shows the characteristics of each study. All studies in the review were assigned an LOE B, due to the inclusion of only case-control and cohort type of studies.

3.4 Syntheses of Results

Overall, almost 87% of the eligible articles investigated the temporal lobe, yielding a total of 100 articles. A total of 22 articles investigated the frontal lobe, while the parietal lobe was investigated in 18 articles. The occipital lobe was the least studied, and was found to be investigated in only 7 articles. Several other cortical and subcortical regions were investigated in a total of 29 studies.

3.4.1 Frontal lobe

From Table 2, most studies reported that APOE ϵ 4 carriers demonstrated reduced GMv and/ or increased rate of atrophy of the frontal lobe as a whole or its specific regions which included the following: left frontal lobe. However, in an APOE ϵ 4 dose-dependent manner, the evidence regarding the direction of change of frontal lobe GMv are conflicting. A few studies also found APOE ϵ 4 carriers to demonstrate thinner cortex in the following regions: bilateral lateral frontal, left rostral midfrontal, right caudal midfrontal regions, superior frontal gyrus, and dorsolateral frontal regions. This contrasts with studies that found increased cortical thickening of the lateral medial orbitofrontal cortical region (Chang et al., 2016), and dorsolateral frontal region (Sampedro et al., 2015; Fan et al 2010). The left side region of the dorsolateral region was found to show increased cortical thickening compared to the right, as indicated by Fan et al. (2010). Several studies did not identify an effect of APOE ϵ 4 on either the frontal lobe size, or on the side of the caudal and rostral middle, superior, inferior, and orbitofrontal regions. There is evidence of the lack of an association between APOE ϵ 4 and frontal lobe atrophy, and several of its regions i.e. right superior frontal gyrus, the lateral and medial frontal region. Nevertheless, an association was found between APOE ϵ 4 and reduced GMv in the inferior frontal lobe (Chen et al 2012), and the dorsolateral frontal region (Sampedro et al., (2015). Another study postulated that there was no association between APOE ϵ 4 and cortical thinning of the inferior frontal cortex (Sabuncu et al., 2012).

Moderate evidence shows reduced middle frontal gyrus size among APOE ϵ 4 carriers (strength of conclusion 2). Some evidence showed cortical thinning in the lateral frontal, left rostral midfrontal, right caudal midfrontal, and superior frontal gyrus in APOE ϵ 4 carriers (strength of conclusion 3). Additionally, there is some evidence of increased cortical thickening of the lateral medial orbitofrontal cortical region (strength of conclusion 3). Moderate evidence showed that there is no APOE ϵ 4 effect on the frontal lobe (strength of conclusion 2), while there is some evidence on the lack of influence of APOE ϵ 4 on specific regions of the frontal lobe, specifically the caudal and rostral middle, superior, inferior, and orbitofrontal regions (strength of conclusion 3). There is moderate evidence of the lack of association between APOE ϵ 4 and the frontal lobe (strength of conclusion 2).

3.4.2 Parietal lobe

From the studies, APOE ϵ 4 carriers were found to demonstrate cortical thinning in the medial, lateral parietal, inferior parietal, precuneus, left parietal gyrus, superior parietal gyrus, angular gyrus, and the right hemisphere of the parietal lobe. Contrarily, APOE ϵ 4 carriers were reported in other studies to demonstrated increased cortical thickness in the precuneus, inferior parietal region, and the right parietal regions. Although there is contradictory evidence regarding the direction of volumetric change in the parietal lobe in APOE ϵ 4 carriers, its regions such as the right angular gyrus and precuneus were found to be reduced. Furthermore, there is conflicting evidence regarding the association between APOE ϵ 4 and parietal atrophy; however some reports show association between APOE ϵ 4 and the inferior and superior parietal cortices. There is abundant evidence pointing to an association between APOE ϵ 4 status and increased rates of cortical thinning in the precuneus among MCI patients. Contrarily, there was a report of an absence of a significant association between APOE ϵ 4 and the size of the inferior parietal cortex and sulcus (Sabuncu et al., 2012). There are conflicting evidence regarding the effect of APOE ϵ 4 on the parietal lobe cortical region.

In conclusion, there is evidence that APOE ϵ 4 carriers show cortical thinning in the medial lateral parietal and left parietal gyrus (strength of conclusion 3). There is moderate evidence that APOE ϵ 4 carriers demonstrate cortical thinning in the superior parietal gyrus (strength of conclusion 2). There is moderate evidence that the cortical thickness of the precuneus changes in APOE ϵ 4 carriers (strength of conclusion 2). However, inconclusive evidence exists regarding the direction of change of cortical thickness in the precuneus, and inferior parietal region in APOE ϵ 4 carriers (strength of conclusion 4). There is moderate evidence of GM changes in the parietal lobe in APOE ϵ 4 carriers (strength of conclusion 2). There is moderate evidence that GMv in the precuneus is reduced in APOE ϵ 4 carriers (strength of conclusion 2).

3.4.3 Temporal lobe

3.4.3.1 Hippocampus

Several studies consistently reported that APOE ϵ 4 carriers exhibited decreased hippocampal GMv or cortical thinning and/ or observed association between APOE ϵ 4 and reduced hippocampal GMv. An interesting point is that apart from these studies engaging older adults the majority of these studies also involved MCI and/ or AD patients with or without healthy

controls (HCs). Several studies did not find any effect of APOE ϵ 4 on reduced hippocampal GMV or size reduction rate. However, there is evidence of increased APOE ϵ 4 dose effects on hippocampal atrophy. Several studies did not find an association between APOE ϵ 4 dose effect and reduced hippocampal GMV or cortical thinning measurements. However a study (Kerchner et al., 2014) found an association between APOE ϵ 4 dose effect on cortical thinning of the hippocampal subregions.

In conclusion, moderate evidence shows that the hippocampal volume is not only reduced in APOE ϵ 4 carriers but it is also associated with APOE ϵ 4 (strength of conclusion 2). Furthermore, there is moderate evidence of reduced cortical thickness or GMV of some hippocampal subfields (CA1-3, dentate gyrus, and subiculum) (strength of conclusion 2). Some evidence shows that APOE ϵ 4 dose effect is associated with cortical thinning of the hippocampal subregions (strength of conclusion 3). Moderate evidence shows that APOE ϵ 4 has no effect on hippocampal atrophy or rate of atrophy (strength of conclusion 2). However there is moderate evidence that increased APOE ϵ 4 dose effects is observed on hippocampal atrophy (strength of conclusion 2). Further, moderate evidence shows the lack of association between APOE ϵ 4 dose effect and hippocampal atrophy or volume (strength of conclusion 2). There is moderate evidence of decreased cortical thickness in the hippocampal subregions (strength of conclusion 2). There is evidence to show that APOE ϵ 4 exerts no significant effect on hippocampal thickness (strength of conclusion 3).

3.4.3.2 Amygdala

Several studies reported consistent reduction of volumetric measures, or atrophy, and increased atrophy rate of the amygdala in APOE ϵ 4 carriers. These studies suggest age-related atrophy of the amygdala similar to what was observed in the hippocampus. There are conflicting reports regarding the effect of APOE ϵ 4 on amygdala volume. Furthermore, reports on amygdala asymmetry in APOE ϵ 4 carriers are conflicting.

In conclusion, there is moderate evidence of reduced amygdala volumes in older individuals with MCI and AD compared to HCs (strength of conclusion 2). However, there is inconclusive evidence regarding the effect of APOE ϵ 4 on amygdala volumes or its atrophy, and symmetrical differences in demented and non-demented older adults (strength of conclusion 4).

3.4.3.3 Entorhinal Cortex

Consistently, APOE ϵ 4 carriers were found to exhibit cortical thinning (or reduced volume) in the entorhinal cortex. However, one study found the opposite which was observed in younger participants (DiBattista et al., 2014). Furthermore, reports of effect or an association between APOE ϵ 4 and entorhinal cortical atrophy/thinning or its rate of reduction are conflicting. Interestingly, a single study observed an association between APOE ϵ 4 and increased entorhinal cortical thickening among those with early MCI and HCs (Li et al., 2017).

In conclusion, moderate evidence shows that APOE ϵ 4 carriers demonstrate cortical thinning in the entorhinal cortex (strength of conclusion 2). There is indistinct evidence regarding the effect of APOE ϵ 4 and likewise the association between APOE ϵ 4 and entorhinal size reduction (strength of conclusion 4).

3.4.3.4 Parahippocampal gyrus

Parahippocampal gyrus was found to demonstrate decreased cortical thickening or increased atrophy or rate of reduction among APOE ϵ 4 carriers who were within the older age bracket. No evidence of APOE ϵ 4 effect was observed on the parahippocampal gyrus. There is strong evidence to support that APOE ϵ 4 carrier status is associated with reduced GMv (or thickness) or increased rate of atrophy in the parahippocampal gyrus. Interestingly, one study found an association between APOE ϵ 4 and increased cortical thickening in the parahippocampal gyrus in healthy participants and those with early MCI.

In conclusion, moderate evidence shows that APOE ϵ 4 carriers demonstrate reduced cortical thickening, increased atrophy, or increased rate of atrophy in the parahippocampal gyrus (strength of conclusion 2). Further, moderate evidence shows no APOE ϵ 4 effect on parahippocampal gyrus (strength of conclusion 2). Additionally, moderate evidence shows that APOE ϵ 4 is associated with reduced volume and increased rate of atrophy of the parahippocampal gyrus (strength of conclusion 2).

3.4.3.5 Other temporal lobe regions of interest

An interesting point to highlight is the report of increased cortical thickness in APOE ϵ 2 carriers relative to APOE ϵ 4 carriers (Konishi et al., 2016; Groot et al., 2016). This suggests that APOE ϵ 2 may offer some protective role against dementia in both young adults older age group.

In conclusion, from Table 2, there is reasonable evidence that APOE ϵ 4 carriers demonstrate reduced GMv in the middle temporal lobe, temporal pole, and in general, the whole temporal lobe (strength of conclusion 2). Further, some evidence shows that APOE ϵ 4 carriers

demonstrate reduced cortical thinning in the middle temporal gyrus, and medial and temporal regions; and GMv reduction or rate of reduction in the fusiform, temporoparietal and occipitotemporal regions (strength of conclusion 3). Conversely, some evidence shows that male APOE ϵ 4 carriers demonstrate increased cortical thickening in the temporoparietal regions (strength of conclusion 3). Furthermore, there is moderate evidence that APOE ϵ 4 is associated with increased rate of cortical thinning in temporoparietal cortex, and that APOE ϵ 4 does not exert an effect on temporal lobe volume (strength of conclusion 2). There is also some evidence that APOE ϵ 4 is associated with lower cortical thickening of the temporal lobe cortex and reduced GMv in the fusiform gyrus and temporal pole cortex (strength of conclusion 3).

3.4.4 Occipital lobe

APOE ϵ 4 carriers were reported to demonstrate increased GMv in the left middle occipital cortex in a dose-dependent manner, with evidence of increased rate of atrophy in bilateral lingual gyri in APOE ϵ 4 carriers. Increased cortical thickening was found in the occipital region, and in the right hemisphere in the occipital region specifically in male APOE ϵ 4 carriers. On the other hand, the occipital region was reported to demonstrate cortical thinning in APOE ϵ 4 carriers. One study found no association between APOE ϵ 4 and atrophy of the occipital lobe (Doody et al., 2000). A single study found an association between APOE ϵ 4 and decreased volume of right lingual gyrus (Tosun et al., 2010), and another found an association between APOE ϵ 4 and lower volumes of the left cuneus (Yokoyama et al., 2015).

In conclusion, although there is evidence of increased GMv or cortical thickness in some cortical regions of the occipital lobe in APOE ϵ 4 carriers, only the bilateral lingual gyri were found to demonstrate atrophy APOE ϵ 4 carriers (strength of conclusion 3). This is reflected in the differences in the association between APOE ϵ 4 and occipital lobe or its regions.

3.4.5 Other cortical gray matter regions

In conclusion, based on the evidence presented in Table 2, it is clear that there is some evidence that APOE ϵ 4 carriers showed decreased GMv in the insula, and several regions of the cingulate cortex (strength of conclusion 3). Further, some evidence shows an association between APOE ϵ 4 and reduced GMv in the anterior cingulate, cerebral cortex; and between APOE ϵ 4 and increased cortical thickness in the right caudal anterior cingulate cortex (strength of conclusion 3). Also, there is some evidence that APOE ϵ 4 has no effect on the cortical thickness of bilateral cingulate cortices in AD patients (strength of conclusion 3). However, there is some evidence of additive effect of APOE ϵ 4 on reduced GMv in the right cerebellar

crus (strength of conclusion 3). There is moderate evidence of reduced GMv and lower cortical thickening in the posterior cingulate cortex (PCC) in APOE ϵ 4 carriers (strength of conclusion 2). There is some evidence that APOE ϵ 4 exerts an effect on cerebral cortex atrophy (strength of conclusion 3). However there is lack of association between APOE ϵ 4 and cerebral volume (strength of conclusion 2), and cerebellar GMv reduction (strength of conclusion 3).

3.4.6 Other subcortical gray matter regions

In summary, based on the findings shown in Table 2, APOE ϵ 4 may have minimal to no effect on the size of the thalamus from young to middle age, while in older adults, it may exert more negative effect (strength of conclusion 3). Further, some evidence shows that older adult APOE ϵ 4 carriers with MCI exhibit increased GM atrophy of the thalamus (strength of conclusion 3). There is some evidence of increased rate of subcortical atrophy of the putamen and loss of GM in the right caudate nucleus in APOE ϵ 4 carriers (strength of conclusion 3). Inconclusive evidence exists regarding the association between APOE ϵ 4 carriers and basal ganglia GMv (strength of conclusion 4). Some evidence shows subcortical atrophy in the accumbens, right ventral striatum and sulcal widening among APOE ϵ 4 carriers (strength of conclusion 3).

4.0 Discussion

Several neuroplastic changes were found to occur not only in cortical areas of GM, but several subcortical regions in individuals carrying the APOE ϵ 4 allele relative to noncarriers. These changes have often manifested as reduced GMVs or cortical thinning in both cortical and subcortical structures. Patterns of GM thinning is thought to be reflective of synaptic pruning size alterations and number of glia or neuronal size (Huttenlocher, 1979; Cotter et al., 2002). GMv reduction in the middle frontal gyrus may provide better insight regarding the underlying pathophysiological changes that occur in APOE ϵ 4 carriers, compared to changes in the right lateral orbitofrontal cortex or lateral prefrontal cortex. MRI studies reveal that to some extent, the cortical thinning in the frontal lobe subcortical structures i.e. the lateral frontal, left rostral midfrontal, right caudal midfrontal, and superior frontal gyrus; and increased cortical thickening in the lateral medial orbitofrontal cortical region in APOE ϵ 4 carriers may be of clinical significance. Overall, it appears that the cortical thickness measurements of the frontal lobe subcortical structures may be able to elicit more neuroplastic changes compared to GMv measurements.

Decreased volumes in specific parietal lobe subcortical structures i.e. right angular gyrus, may provide valuable details about structural changes in APOE ϵ 4 carriers. We noted that the cortical thinning in the superior parietal gyrus appear to better reflect the effect of APOE carrier status with neurodegeneration. The NIA-AA guidelines recommend that the presence of cortical thinning or GMv loss in the lateral and medial parietal gyri is a marker of AD-pathophysiology (Sperling et al., 2011). Nevertheless, we did find strong evidence to support medial and lateral parietal lobe atrophy in the APOE carriers. In fact, Mattson et al (2018) detected increased cortical thickness of these regions among the APOE positive carriers as compared to non-carriers. Similar findings have been noted by Chételat et al. (2010) and Johnson et al., 2014, whereby amyloid positive individuals demonstrated increased GMv in the temporal and lateral parietal regions, which was postulated to be due to brain swelling associated with glial activation in preclinical AD stages (Chételat et al., 2010; Johnson, 2014). There is consistent reports of precuneal GMv reduction and its association with APOE ϵ 4. The precuneus together with the PCC has been the main focus of several studies investigating cognitively normal individuals and/or AD because it is recognized as one of the key regions that demonstrates cortical thinning (Lehmann et al., 2010), hypometabolism on ^{18}F -fluorodeoxyglucose (FDG)-PET (Minoshima et al., 1997), lower levels of N-acetyl aspartate/creatine, elevated myoinositol/Cr (Voevodskaya et al., 2016; Suri et al., 2017), and histopathologic changes (Braak and Braak,

1991) in the early course of AD. This may suggest that precuneal GM volumetry may better provide insight on neuronal injury compared to cortical thickness measures.

There is strong evidence showing that APOE ϵ 4 carriers demonstrate reduced cortical thickening or increased GMv reduction in medial temporal lobe regions (hippocampus, amygdala, entorhinal cortex, and parahippocampal gyrus) widely known to play significant roles in memory and implicated in neural correlates of AD. An important highlight to the reduction of cortical thickening in the hippocampus is the involvement of its subfields (CA1-3, dentate gyrus, and subiculum) which appear to be largely driven by old age. There are proponents of the hippocampal subfield volumetric measures in place of the traditional whole hippocampal volumetry as AD biomarker (Maruszak and Thuret, 2014; La Joie et al., 2013). This stems from evidence of differences in vulnerability of the hippocampal subfields to AD neuropathology (Braak and Braak, 1991; Braak and Braak, 1993). The findings on the effect and association between APOE ϵ 4 and amygdala, entorhinal cortex, and parahippocampal gyrus is mixed, suggesting their limitation as potential AD biomarkers.

The occipital lobe is the least studied, possibly due to the reason that visual symptoms are uncommon and that this region is not usually affected until relatively late in the neocortical stages of AD (Smith et al. 2001). From the findings, it seems plausible to suggest that the whole occipital lobe may better provide insight regarding structural changes among APOE ϵ 4 carriers compared to its subcortical regions. The PCC may be an important structure to earmark for analysis during the pathophysiological process of AD or in healthy individuals with APOE ϵ 4.

To put these results into a broad perspective, these findings expand our knowledge that apart from cortical structures widely touted as being influenced by APOE ϵ 4, subcortical structures especially that of the medial temporal lobe are also vulnerable and influenced to a large extent by advanced age, and APOE ϵ 4 carriership.

4.1 Strengths and Limitations.

Compared with previous systematic reviews and meta-analysis (Liu et al., 2015; Cherbuin et al., 2007), the current study did not restrict the inclusion criteria to the number of sample sizes, age of participants, and regional structures investigated in each study. Further, a level of evidence B was assigned because comparative studies including patient-control studies and cohort studies were included. However, the studies identified showed great variation in a number of variables, i.e. the magnetic field strength, MRI parameters, measurement and analytic methods, region(s) of interest studied, disproportionate distribution of sample size and gender, age range or average age, and differences in measuring tools applied for determining cognitive status of participants. It is possible that these variations to some extent may have led

to a few of the discordant findings reported. Nonetheless, the results are striking in that there is much consistency in structural alterations in APOE ϵ 4 carriers.

5.0 Conclusions

The present data supports analyzing the hippocampal GM volume in particular as part of the diagnostic process in healthy individuals with APOE ϵ 4 and those at risk of developing AD. Further the study supports the use of hippocampal atrophy as an invaluable AD biomarker that can contribute to tracking progressive structural brain alterations different age group who are APOE ϵ 4 carriers. However, further longitudinal studies may be necessary to confirm whether a combination of both hippocampal atrophy and APOE ϵ 4 will be capable of predicting the development of AD in healthy individuals.

Author contributions

Conception and study design (ADP, MM), data collection (ADP), interpretation of results (ADP, MM, and SS); drafting the manuscript work or revising it critically for important intellectual content (ADP, MM, SS, and NFR); approval of final version to be published and agreement to be accountable for the integrity and accuracy of all aspects of the work (ADP, MM, SS, and NFR).

Compliance with Ethical Standards

Funding: None

Conflict of Interest: The authors declare that they have no conflict of interest.

Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent: Informed consent was obtained from all individual participants included in the studies reviewed in this paper.

References

- Aleman, S., Vilor-Tejedor, N., García-Esteban, R., Bustamante, M., Dadvand, P., Esnaola, M., Mortamais, M., Forn, J., van Drooge, B. L., Álvarez-Pedrerol, M., Grimalt, J. O., Rivas, I., Querol, X., Pujol, J., & Sunyer, J. (2018). Traffic-Related Air Pollution, APOE ϵ 4 Status, and Neurodevelopmental Outcomes among School Children Enrolled in the BREATHE Project (Catalonia, Spain). *Environmental health perspectives*, 126(8), 087001. <https://doi.org/10.1289/EHP2246>
- Alzheimer's Association. (2020). Alzheimer's disease Facts and Figures. *Alzheimer's Dement*, 16, 391–460.
- Andrawis, J. P., Hwang, K. S., Green, A. E., Kotlerman, J., Elashoff, D., Morra, J. H., Cummings, J. L., Toga, A. W., Thompson, P. M., & Apostolova, L. G. (2012). Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. *Neurobiology of aging*, 33(5), 856–866. <https://doi.org/10.1016/j.neurobiolaging.2010.07.020>
- Barber, R., Gholkar, A., Scheltens, P., Ballard, C., McKeith, I. G., Morris, C. M., & O'Brien, J. T. (1999). Apolipoprotein E ϵ 4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias. *Archives of Neurology*, 56(8), 961.
- Barber, R., Ballard, C., McKeith, I. G., Gholkar, A., & O'Brien, J. T. (2000). MRI volumetric study of dementia with Lewy bodies: A comparison with AD and vascular dementia. *Neurology*, 54(6), 1304–1309.
- Basso, M., Gelernter, J., Yang, J., MacAvoy, M. G., Varma, P., Bronen, R. A., & van Dyck, C. H. (2006). Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. *Neurobiology of Aging*, 27(10), 1416–1424.
- Bigler, E. D., Tate, D. F., Miller, M. J., Rice, S. A., Hessel, C. D., Earl, H. D., Tschanz, J. T., Plassman, B., & Welsh-Bohmer, K. A. (2002). Dementia, asymmetry of temporal lobe structures, and apolipoprotein E genotype: relationships to cerebral atrophy and neuropsychological impairment. *Journal of the International Neuropsychological Society : JINS*, 8(7), 925–933.
- Boccardi, M., Sabattoli, F., Testa, C., Beltramello, A., Soininen, H., & Frisoni, G. B. (2004). APOE and modulation of Alzheimer's and frontotemporal dementia. *Neuroscience letters*, 356(3), 167–170.

Braak, H., & Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. *Acta neuropathologica*, 82(4), 239–259.

Braak, H., Braak, E., & Bohl, J. (1993). Staging of Alzheimer-related cortical destruction. *European neurology*, 33(6), 403–408.

Bussy, A., Snider, B. J., Coble, D., Xiong, C., Fagan, A. M., Cruchaga, C., Benzinger, T., Gordon, B. A., Hassenstab, J., Bateman, R. J., Morris, J. C., & Dominantly Inherited Alzheimer Network (2019). Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. *Neurobiology of aging*, 75, 42–50.

Burggren, A. C., Zeineh, M. M., Ekstrom, A. D., Braskie, M. N., Thompson, P. M., Small, G. W., & Bookheimer, S. Y. (2008). Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. *NeuroImage*, 41(4), 1177–1183.

Bender, A. R., & Raz, N. (2012). Age-related differences in memory and executive functions in healthy APOE ϵ 4 carriers: the contribution of individual differences in prefrontal volumes and systolic blood pressure. *Neuropsychologia*, 50(5), 704–714.

Banks, S. J., Miller, J. B., Rissman, R. A., & Bernick, C. B. (2017). Lack of Influence of Apolipoprotein E Status on Cognition or Brain Structure in Professional Fighters. *Journal of neurotrauma*, 34(2), 380–384.

Barboriak, D. P., Doraiswamy, P. M., Krishnan, K. R., Vidyarthi, S., Sylvester, J., & Charles, H. C. (2000). Hippocampal sulcal cavities on MRI: relationship to age and apolipoprotein E genotype. *Neurology*, 54(11), 2150–2153.

Biffi, A., Anderson, C. D., Desikan, R. S., Sabuncu, M., Cortellini, L., Schmansky, N., Salat, D., Rosand, J., & Alzheimer's Disease Neuroimaging Initiative (ADNI) (2010). Genetic variation and neuroimaging measures in Alzheimer disease. *Archives of neurology*, 67(6), 677–685.

Bunce, D., Anstey, K. J., Cherbuin, N., Gautam, P., Sachdev, P., & Easteal, S. (2012). APOE genotype and entorhinal cortex volume in non-demented community-dwelling adults in midlife and early old age. *Journal of Alzheimer's disease : JAD*, 30(4), 935–942.

Cacciaglia, R., Molinuevo, J. L., Falcón, C., Brugulat-Serrat, A., Sánchez-Benavides, G., Gramunt, N., Esteller, M., Morán, S., Minguillón, C., Fauria, K., Gispert, J. D., & ALFA study (2018). Effects of APOE- ϵ 4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease. *Alzheimer's & dementia: the journal of the Alzheimer's Association*, 14(7), 902–912.

Carmelli, D., DeCarli, C., Swan, G. E., Kelly-Hayes, M., Wolf, P. A., Reed, T., & Guralnik, J. M. (2000). The joint effect of apolipoprotein E epsilon4 and MRI findings on lower-extremity function and decline in cognitive function. *The journals of gerontology. Series A, Biological sciences and medical sciences*, 55(2), M103–M109.

Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., Goate, A. M., Bales, K. R., Paul, S. M., Bateman, R. J., & Holtzman, D. M. (2011). Human apoE isoforms differentially regulate brain amyloid- β peptide clearance. *Science translational medicine*, 3(89), 89ra57.

Chang, Y. L., Fennema-Notestine, C., Holland, D., McEvoy, L. K., Stricker, N. H., Salmon, D. P., Dale, A. M., Bondi, M. W., & Alzheimer's Disease Neuroimaging Initiative (2014). APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 10(3), 336–348.

Chang, L., Douet, V., Bloss, C., Lee, K., Pritchett, A., Jernigan, T. L., Akshoomoff, N., Murray, S. S., Frazier, J., Kennedy, D. N., Amaral, D. G., Gruen, J., Kaufmann, W. E., Casey, B. J., Sowell, E., Ernst, T., & Pediatric Imaging, Neurocognition, and Genetics (PING) Study Consortium (2016). Gray matter maturation and cognition in children with different APOE ϵ genotypes. *Neurology*, 87(6), 585–594.

Chen, K., Ayutyanont, N., Langbaum, J. B., Fleisher, A. S., Reschke, C., Lee, W., Liu, X., Alexander, G. E., Bandy, D., Caselli, R. J., & Reiman, E. M. (2012). Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ϵ 4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares. *NeuroImage*, 60(4), 2316–2322. <https://doi.org/10.1016/j.neuroimage.2012.02.005>

Cherbuin, N., Leach, L. S., Christensen, H., & Anstey, K. J. (2007). Neuroimaging and APOE genotype: a systematic qualitative review. *Dementia and geriatric cognitive disorders*, 24(5), 348–362.

Cherbuin, N., Anstey, K. J., Sachdev, P. S., Maller, J. J., Meslin, C., Mack, H. A., Wen, W., & Easteal, S. (2008). Total and regional gray matter volume is not related to APOE*E4 status in a community sample of middle-aged individuals. *The journals of gerontology. Series A, Biological sciences and medical sciences*, 63(5), 501–504.

Chételat, G., Villemagne, V. L., Pike, K. E., Baron, J. C., Bourgeat, P., Jones, G., Faux, N. G., Ellis, K. A., Salvado, O., Szoek, C., Martins, R. N., Ames, D., Masters, C. L., Rowe, C. C., & Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group (2010). Larger temporal volume in elderly with high versus low beta-amyloid deposition. *Brain: a journal of neurology*, 133(11), 3349–3358.

Coppieters, I., Meeus, M., Kregel, J., Caeyenberghs, K., De Pauw, R., Goubert, D., & Cagnie, B. (2016). Relations Between Brain Alterations and Clinical Pain Measures in Chronic Musculoskeletal Pain: A Systematic Review. *The journal of pain : official journal of the American Pain Society*, 17(9), 949–962.

Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science (New York, N.Y.)*, 261(5123), 921–923.

Cotta Ramusino, M., Altomare, D., Bacchin, R., Ingala, S., Bnà, C., Bonetti, M., Costa, A., Barkhof, F., Nicolosi, V., Festari, C., Frisoni, G. B., & Boccardi, M. (2019). Medial temporal lobe atrophy and posterior atrophy scales normative values. *NeuroImage. Clinical*, 24, 101936. <https://doi.org/10.1016/j.nicl.2019.101936>

Cotter, D., Mackay, D., Chana, G., Beasley, C., Landau, S., & Everall, I. P. (2002). Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. *Cerebral cortex (New York, N.Y. : 1991)*, 12(4), 386–394.

Dean, D. C., 3rd, Jerskey, B. A., Chen, K., Protas, H., Thiyyagura, P., Roontiva, A., O'Muircheartaigh, J., Dirks, H., Waskiewicz, N., Lehman, K., Siniard, A. L., Turk, M. N., Hua, X., Madsen, S. K., Thompson, P. M., Fleisher, A. S., Huentelman, M. J., Deoni, S. C., & Reiman, E. M. (2014). Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. *JAMA neurology*, 71(1), 11–22.

DiBattista, A. M., Stevens, B. W., Rebeck, G. W., & Green, A. E. (2014). Two Alzheimer's disease risk genes increase entorhinal cortex volume in young adults. *Frontiers in human neuroscience*, 8, 779. <https://doi.org/10.3389/fnhum.2014.00779>

Dong, Q., Zhang, W., Wu, J., Li, B., Schron, E. H., McMahon, T., Shi, J., Gutman, B. A., Chen, K., Baxter, L. C., Thompson, P. M., Reiman, E. M., Caselli, R. J., & Wang, Y. (2019). Applying surface-based hippocampal morphometry to study APOE-E4 allele dose effects in cognitively unimpaired subjects. *NeuroImage. Clinical*, 22, 101744.

Donix, M., Burggren, A. C., Suthana, N. A., Siddarth, P., Ekstrom, A. D., Krupa, A. K., Jones, M., Rao, A., Martin-Harris, L., Ercoli, L. M., Miller, K. J., Small, G. W., & Bookheimer, S. Y. (2010). Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-4 polymorphism. *NeuroImage*, 53(1), 37–43. <https://doi.org/10.1016/j.neuroimage.2010.06.009>

Donix, M., Burggren, A. C., Scharf, M., Marschner, K., Suthana, N. A., Siddarth, P., Krupa, A. K., Jones, M., Martin-Harris, L., Ercoli, L. M., Miller, K. J., Werner, A., von Kummer, R., Sauer, C., Small, G. W., Holthoff, V. A., & Bookheimer, S. Y. (2013). APOE associated hemispheric

asymmetry of entorhinal cortical thickness in aging and Alzheimer's disease. *Psychiatry research*, 214(3), 212–220.

Doody, R. S., Azher, S. N., Haykal, H. A., Dunn, J. K., Liao, T., & Schneider, L. (2000). Does APO epsilon4 correlate with MRI changes in Alzheimer's disease?. *Journal of neurology, neurosurgery, and psychiatry*, 69(5), 668–671.

Du, A. T., Schuff, N., Chao, L. L., Kornak, J., Jagust, W. J., Kramer, J. H., Reed, B. R., Miller, B. L., Norman, D., Chui, H. C., & Weiner, M. W. (2006). Age effects on atrophy rates of entorhinal cortex and hippocampus. *Neurobiology of aging*, 27(5), 733–740.
<https://doi.org/10.1016/j.neurobiolaging.2005.03.021>

Espeseth, T., Greenwood, P. M., Reinvang, I., Fjell, A. M., Walhovd, K. B., Westlye, L. T., Wehling, E., Lundervold, A., Rootwelt, H., & Parasuraman, R. (2006). Interactive effects of APOE and CHRNA4 on attention and white matter volume in healthy middle-aged and older adults. *Cognitive, affective & behavioral neuroscience*, 6(1), 31–43.

Falahati, F., Ferreira, D., Muehlboeck, J. S., Eriksdotter, M., Simmons, A., Wahlund, L. O., & Westman, E. (2017). Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid. *NeuroImage. Clinical*, 16, 418–428.

Fan, M., Liu, B., Zhou, Y., Zhen, X., Xu, C., Jiang, T., & Alzheimer's Disease Neuroimaging Initiative (2010). Cortical thickness is associated with different apolipoprotein E genotypes in healthy elderly adults. *Neuroscience letters*, 479(3), 332–336.
<https://doi.org/10.1016/j.neulet.2010.05.092>

Fang, Y., Du, N., Xing, L., Duo, Y., & Zheng, L. (2019). Evaluation of hippocampal volume and serum brain-derived neurotrophic factor as potential diagnostic markers of conversion from amnesic mild cognitive impairment to Alzheimer disease: A STROBE-compliant article. *Medicine*, 98(30), e16604.

Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., Myers, R. H., Pericak-Vance, M. A., Risch, N., & van Duijn, C. M. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA*, 278(16), 1349–1356.

Fennema-Notestine, C., Panizzon, M. S., Thompson, W. R., Chen, C. H., Eyler, L. T., Fischl, B., Franz, C. E., Grant, M. D., Jak, A. J., Jernigan, T. L., Lyons, M. J., Neale, M. C., Seidman, L. J., Tsuang, M. T., Xian, H., Dale, A. M., & Kremen, W. S. (2011). Presence of ApoE ε4 allele associated with thinner frontal cortex in middle age. *Journal of Alzheimer's disease : JAD*, 26 Suppl 3(Suppl 3), 49–60.

Ferencz, B., Laukka, E. J., Lövdén, M., Kalpouzos, G., Keller, L., Graff, C., Wahlund, L. O., Fratiglioni, L., & Bäckman, L. (2013). The influence of APOE and TOMM40 polymorphisms on hippocampal volume and episodic memory in old age. *Frontiers in human neuroscience*, 7, 198. <https://doi.org/10.3389/fnhum.2013.00198>

Filippini, N., Zarei, M., Beckmann, C. F., Galluzzi, S., Borsci, G., Testa, C., Bonetti, M., Beltramello, A., Ghidoni, R., Benussi, L., Binetti, G., & Frisoni, G. B. (2009). Regional atrophy of transcallosal prefrontal connections in cognitively normal APOE epsilon4 carriers. *Journal of magnetic resonance imaging : JMRI*, 29(5), 1021–1026.

Foley, J. M., Salat, D. H., Stricker, N. H., McGlinchey, R. E., Milberg, W. P., Grande, L. J., & Leritz, E. C. (2016). Glucose Dysregulation Interacts With APOE-ε4 to Potentiate Temporoparietal Cortical Thinning. *American journal of Alzheimer's disease and other dementias*, 31(1), 76–86.

Foley, S. F., Tansey, K. E., Caseras, X., Lancaster, T., Bracht, T., Parker, G., Hall, J., Williams, J., & Linden, D. E. (2017). Multimodal Brain Imaging Reveals Structural Differences in Alzheimer's Disease Polygenic Risk Carriers: A Study in Healthy Young Adults. *Biological psychiatry*, 81(2), 154–161.

Geroldi, C., Pihlajamäki, M., Laakso, M. P., DeCarli, C., Beltramello, A., Bianchetti, A., Soininen, H., Trabucchi, M., & Frisoni, G. B. (1999). APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. *Neurology*, 53(8), 1825–1832.

Geroldi, C., Laakso, M. P., DeCarli, C., Beltramello, A., Bianchetti, A., Soininen, H., Trabucchi, M., & Frisoni, G. B. (2000). Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease: a volumetric MRI study. *Journal of neurology, neurosurgery, and psychiatry*, 68(1), 93–96.

Ghisays, V., Goradia, D. D., Protas, H., Bauer, R. J., 3rd, Devadas, V., Tariot, P. N., Lowe, V. J., Knopman, D. S., Petersen, R. C., Jack, C. R., Jr, Caselli, R. J., Su, Y., Chen, K., & Reiman, E. M. (2020). Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 16(4), 598–609.

Goltermann, J., Redlich, R., Dohm, K., Zaremba, D., Repple, J., Kaehler, C., Grotegerd, D., Förster, K., Meinert, S., Enneking, V., Schlaghecken, E., Fleischer, L., Hahn, T., Kugel, H., Jansen, A., Krug, A., Brosch, K., Nenadic, I., Schmitt, S., Stein, F., ... Opel, N. (2019). Apolipoprotein E Homozygous ε4 Allele Status: A Deteriorating Effect on Visuospatial Working Memory and Global Brain Structure. *Frontiers in neurology*, 10, 552. <https://doi.org/10.3389/fneur.2019.00552>

Groot, C., Sudre, C. H., Barkhof, F., Teunissen, C. E., van Berckel, B., Seo, S. W., Ourselin, S., Scheltens, P., Cardoso, M. J., van der Flier, W. M., & Ossenkuppe, R. (2018). Clinical phenotype, atrophy, and small vessel disease in APOE ϵ 2 carriers with Alzheimer disease. *Neurology*, 91(20), e1851–e1859.

Habes, M., Toledo, J. B., Resnick, S. M., Doshi, J., Van der Auwera, S., Erus, G., Janowitz, D., Hegenscheid, K., Homuth, G., Völzke, H., Hoffmann, W., Grabe, H. J., & Davatzikos, C. (2016). Relationship between APOE Genotype and Structural MRI Measures throughout Adulthood in the Study of Health in Pomerania Population-Based Cohort. *AJNR. American journal of neuroradiology*, 37(9), 1636–1642.

Haller, S., Montandon, M. L., Rodriguez, C., Ackermann, M., Herrmann, F. R., & Giannakopoulos, P. (2017). APOE*E4 Is Associated with Gray Matter Loss in the Posterior Cingulate Cortex in Healthy Elderly Controls Subsequently Developing Subtle Cognitive Decline. *AJNR. American journal of neuroradiology*, 38(7), 1335–1342.

Hays, C. C., Zlatar, Z. Z., Meloy, M. J., Bondi, M. W., Gilbert, P. E., Liu, T. T., Helm, J. L., & Wierenga, C. E. (2019). APOE modifies the interaction of entorhinal cerebral blood flow and cortical thickness on memory function in cognitively normal older adults. *NeuroImage*, 202, 116162.

Herrmann, F. R., Rodriguez, C., Haller, S., Garibotto, V., Montandon, M. L., & Giannakopoulos, P. (2019). Gray Matter Densities in Limbic Areas and APOE4 Independently Predict Cognitive Decline in Normal Brain Aging. *Frontiers in aging neuroscience*, 11, 157.

Hobel, Z., Isenberg, A. L., Raghupathy, D., Mack, W., Pa, J., & Alzheimer's Disease Neuroimaging Initiative and the Australian Imaging Biomarkers and Lifestyle flagship study of ageing (2019). APOE ϵ 4 Gene Dose and Sex Effects on Alzheimer's Disease MRI Biomarkers in Older Adults with Mild Cognitive Impairment. *Journal of Alzheimer's disease : JAD*, 71(2), 647–658.

Hussin, N. M., Shahar, S., Yahya, H. M., Din, N. C., Singh, D., & Omar, M. A. (2019). Incidence and predictors of mild cognitive impairment (MCI) within a multi-ethnic Asian populace: a community-based longitudinal study. *BMC public health*, 19(1), 1159.

Huttenlocher P. R. (1979). Synaptic density in human frontal cortex - developmental changes and effects of aging. *Brain research*, 163(2), 195–205.

Kaur, M., & Balgir, P. P. (2005). APOE2 and consanguinity: a risky combination for Alzheimer's disease. *Journal of Alzheimer's disease : JAD*, 8(3), 293–297.

Kelly, D. A., Seidenberg, M., Reiter, K., Nielson, K. A., Woodard, J. L., Smith, J. C., Durgerian, S., & Rao, S. M. (2018). Differential 5-year brain atrophy rates in cognitively declining and stable APOE- ϵ 4 elders. *Neuropsychology*, 32(6), 647–653.

Kerchner, G. A., Berdnik, D., Shen, J. C., Bernstein, J. D., Fenesy, M. C., Deutsch, G. K., Wyss-Coray, T., & Rutt, B. K. (2014). APOE ϵ 4 worsens hippocampal CA1 apical neuropil atrophy and episodic memory. *Neurology*, 82(8), 691–697.

Khan, W., Giampietro, V., Ginestet, C., Dell'Acqua, F., Bouls, D., Newhouse, S., Dobson, R., Banaschewski, T., Barker, G. J., Bokde, A. L., Büchel, C., Conrod, P., Flor, H., Frouin, V., Garavan, H., Gowland, P., Heinz, A., Ittermann, B., Lemaître, H., Nees, F., ... IMAGEN consortium (2014). No differences in hippocampal volume between carriers and non-carriers of the ApoE ϵ 4 and ϵ 2 alleles in young healthy adolescents. *Journal of Alzheimer's disease : JAD*, 40(1), 37–43.

Kirsebom, B. E., Nordengen, K., Selnes, P., Waterloo, K., Torsetnes, S. B., Gísladóttir, B., Brix, B., Vanmechelen, E., Bråthen, G., Hessen, E., Aarsland, D., & Fladby, T. (2018). Cerebrospinal fluid neurogranin/ β -site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. *Alzheimer's & dementia (New York, N. Y.)*, 4, 617–627.

<https://doi.org/10.1016/j.trci.2018.10.003>

Hafsteinsdóttir, S. H., Eiríksdóttir, G., Sigurdsson, S., Aspelund, T., Harris, T. B., Launer, L. J., & Gudnason, V. (2012). Brain tissue volumes by APOE genotype and leisure activity—the AGES-Reykjavik Study. *Neurobiology of aging*, 33(4), 829.e1–829.e8298.

Holland, D., Desikan, R. S., Dale, A. M., McEvoy, L. K., & Alzheimer's Disease Neuroimaging Initiative (2013). Higher rates of decline for women and apolipoprotein E epsilon4 carriers. *AJNR. American journal of neuroradiology*, 34(12), 2287–2293.

Hoogendam, Y. Y., van der Geest, J. N., van der Lijn, F., van der Lugt, A., Niessen, W. J., Krestin, G. P., Hofman, A., Vernooij, M. W., Breteler, M. M., & Ikram, M. A. (2012). Determinants of cerebellar and cerebral volume in the general elderly population. *Neurobiology of aging*, 33(12), 2774–2781.

Honea, R. A., Vidoni, E., Harsha, A., & Burns, J. M. (2009). Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. *Journal of Alzheimer's disease : JAD*, 18(3), 553–564.

Hostage, C. A., Roy Choudhury, K., Doraiswamy, P. M., Petrella, J. R., & Alzheimer's Disease Neuroimaging Initiative (2013). Dissecting the gene dose-effects of the APOE ϵ 4 and ϵ 2 alleles on hippocampal volumes in aging and Alzheimer's disease. *PloS one*, 8(2), e54483.

Hostage, C. A., Choudhury, K. R., Murali Doraiswamy, P., Petrella, J. R., & Alzheimer's Disease Neuroimaging Initiative (2014). Mapping the effect of the apolipoprotein E genotype on 4-year atrophy rates in an Alzheimer disease-related brain network. *Radiology*, 271(1), 211–219.

<https://doi.org/10.1148/radiol.13131041>

Hua, X., Leow, A. D., Parikshak, N., Lee, S., Chiang, M. C., Toga, A. W., Jack, C. R., Jr, Weiner, M. W., Thompson, P. M., & Alzheimer's Disease Neuroimaging Initiative (2008). Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. *NeuroImage*, 43(3), 458–469.

Ibrahim, A., Singh, D., & Shahar, S. (2017). 'Timed Up and Go' test: Age, gender and cognitive impairment stratified normative values of older adults. *PloS one*, 12(10), e0185641.

Jak, A. J., Houston, W. S., Nagel, B. J., Corey-Bloom, J., & Bondi, M. W. (2007). Differential cross-sectional and longitudinal impact of APOE genotype on hippocampal volumes in nondemented older adults. *Dementia and geriatric cognitive disorders*, 23(6), 382–389.

Johnson, S. C., Christian, B. T., Okonkwo, O. C., Oh, J. M., Harding, S., Xu, G., Hillmer, A. T., Wooten, D. W., Murali, D., Barnhart, T. E., Hall, L. T., Racine, A. M., Klunk, W. E., Mathis, C. A., Bendlin, B. B., Gallagher, C. L., Carlsson, C. M., Rowley, H. A., Hermann, B. P., Dowling, N. M., ... Sager, M. A. (2014). Amyloid burden and neural function in people at risk for Alzheimer's Disease. *Neurobiology of aging*, 35(3), 576–584.

Juottonen, K., Lehtovirta, M., Helisalmi, S., Riekkinen, P. J., Sr, & Soininen, H. (1998). Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele. *Journal of neurology, neurosurgery, and psychiatry*, 65(3), 322–327. <https://doi.org/10.1136/jnnp.65.3.322>

Khan, W., Giampietro, V., Banaschewski, T., Barker, G. J., Bokde, A. L., Büchel, C., Conrod, P., Flor, H., Frouin, V., Garavan, H., Gowland, P., Heinz, A., Ittermann, B., Lemaître, H., Nees, F., Paus, T., Pausova, Z., Rietschel, M., Smolka, M. N., Ströhle, A., ... IMAGEN consortium (2017). A Multi-Cohort Study of ApoE ϵ 4 and Amyloid- β Effects on the Hippocampus in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*, 56(3), 1159–1174.

Konishi, K., Bhat, V., Banner, H., Poirier, J., Joobar, R., & Bohbot, V. D. (2016). APOE2 Is Associated with Spatial Navigational Strategies and Increased Gray Matter in the Hippocampus. *Frontiers in human neuroscience*, 10, 349. <https://doi.org/10.3389/fnhum.2016.00349K>

Konishi, K., Joobar, R., Poirier, J., MacDonald, K., Chakravarty, M., Patel, R., Breitner, J., & Bohbot, V. D. (2018). Healthy versus Entorhinal Cortical Atrophy Identification in Asymptomatic APOE4 Carriers at Risk for Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*, 61(4), 1493–1507.

Koval, I., Schiratti, J. B., Routier, A., Bacci, M., Colliot, O., Allasonnière, S., & Durrleman, S. (2018). Spatiotemporal Propagation of the Cortical Atrophy: Population and Individual Patterns. *Frontiers in neurology*, 9, 235.

La Joie, R., Perrotin, A., de La Sayette, V., Egret, S., Doeuvre, L., Belliard, S., Eustache, F., Desgranges, B., & Chételat, G. (2013). Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia. *NeuroImage. Clinical*, 3, 155–162.

Lampert, E. J., Roy Choudhury, K., Hostage, C. A., Rathakrishnan, B., Weiner, M., Petrella, J. R., Doraiswamy, P. M., & Alzheimer's Disease Neuroimaging Initiative (2014). Brain atrophy rates in first degree relatives at risk for Alzheimer's. *NeuroImage. Clinical*, 6, 340–346.

Lee, L. K., Shahar, S., Chin, A. V., Mohd Yusoff, N. A., Rajab, N., & Aziz, S. A. (2012). Prevalence of gender disparities and predictors affecting the occurrence of mild cognitive impairment (MCI). *Archives of gerontology and geriatrics*, 54(1), 185–191.

Lehmann, M., Rohrer, J. D., Clarkson, M. J., Ridgway, G. R., Scahill, R. I., Modat, M., Warren, J. D., Ourselin, S., Barnes, J., Rossor, M. N., & Fox, N. C. (2010). Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer's disease. *Journal of Alzheimer's disease : JAD*, 20(2), 587–598.

Lehtovirta, M., Laakso, M. P., Soininen, H., Helisalmi, S., Mannermaa, A., Helkala, E. L., Partanen, K., Ryyänänen, M., Vainio, P., & Hartikainen, P. (1995). Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. *Neuroscience*, 67(1), 65–72

Lehtovirta, M., Soininen, H., Laakso, M. P., Partanen, K., Helisalmi, S., Mannermaa, A., Ryyänänen, M., Kuikka, J., Hartikainen, P., & Riekkinen, P. J., Sr (1996). SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. *Journal of neurology, neurosurgery, and psychiatry*, 60(6), 644–649.

Li, B., Shi, J., Gutman, B. A., Baxter, L. C., Thompson, P. M., Caselli, R. J., Wang, Y., & Alzheimer's Disease Neuroimaging Initiative (2016). Influence of APOE Genotype on Hippocampal Atrophy over Time - An N=1925 Surface-Based ADNI Study. *PloS one*, 11(4), e0152901.

Li, C., Loewenstein, D. A., Duara, R., Cabrerizo, M., Barker, W., Adjouadi, M., & Alzheimer's Disease Neuroimaging Initiative (2017). The Relationship of Brain Amyloid Load and APOE Status to Regional Cortical Thinning and Cognition in the ADNI Cohort. *Journal of Alzheimer's disease : JAD*, 59(4), 1269–1282.

Li, Z., Yang, N., Lei, X., Lin, C., Li, N., Jiang, X., Wei, X., & Xu, B. (2019). The association between the ApoE polymorphisms and the MRI-defined intracranial lesions in a cohort of southern China population. *Journal of clinical laboratory analysis*, 33(7), e22950.

Liu, Y., Yu, J. T., Wang, H. F., Han, P. R., Tan, C. C., Wang, C., Meng, X. F., Risacher, S. L., Saykin, A. J., & Tan, L. (2015). APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis. *Journal of neurology, neurosurgery, and psychiatry*, 86(2), 127–134.

Lu, P. H., Thompson, P. M., Leow, A., Lee, G. J., Lee, A., Yanovsky, I., Parikshak, N., Khoo, T., Wu, S., Geschwind, D., & Bartzokis, G. (2011). Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study. *Journal of Alzheimer's disease : JAD*, 23(3), 433–442.
<https://doi.org/10.3233/JAD-2010-101398>

Lupton, M. K., Strike, L., Hansell, N. K., Wen, W., Mather, K. A., Armstrong, N. J., Thalamuthu, A., McMahon, K. L., de Zubicaray, G. I., Assareh, A. A., Simmons, A., Proitsi, P., Powell, J. F., Montgomery, G. W., Hibar, D. P., Westman, E., Tsolaki, M., Kloszewska, I., Soininen, H., Mecocci, P., ... Wright, M. J. (2016). The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. *Neurobiology of aging*, 40, 68–77.

Lyall, D. M., Royle, N. A., Harris, S. E., Bastin, M. E., Maniega, S. M., Murray, C., Lutz, M. W., Saunders, A. M., Roses, A. D., del Valdés Hernández, M. C., Starr, J. M., Porteous, D. J., Wardlaw, J. M., & Deary, I. J. (2013). Alzheimer's disease susceptibility genes APOE and TOMM40, and hippocampal volumes in the Lothian birth cohort 1936. *PloS one*, 8(11), e80513.

Lyall, D. M., Cox, S. R., Lyall, L. M., Celis-Morales, C., Cullen, B., Mackay, D. F., Ward, J., Strawbridge, R. J., McIntosh, A. M., Sattar, N., Smith, D. J., Cavanagh, J., Deary, I. J., & Pell, J. P. (2019). Association between APOE e4 and white matter hyperintensity volume, but not total brain volume or white matter integrity. *Brain imaging and behavior*, 10.1007/s11682-019-00069-9.

Ma, C., Zhang, Y., Li, X., Zhang, J., Chen, K., Liang, Y., Chen, Y., Liu, Z., & Zhang, Z. (2016). Is there a significant interaction effect between apolipoprotein E rs405509 T/T and ϵ 4 genotypes on cognitive impairment and gray matter volume?. *European journal of neurology*, 23(9), 1415–1425.

MacLusky N. J. (2004). Estrogen and Alzheimer's disease: the apolipoprotein connection. *Endocrinology*, 145(7), 3062–3064.

Manning, E. N., Barnes, J., Cash, D. M., Bartlett, J. W., Leung, K. K., Ourselin, S., Fox, N. C., & Alzheimer's Disease Neuroimaging Initiative (2014). APOE ϵ 4 is associated with disproportionate progressive hippocampal atrophy in AD. *PloS one*, 9(5), e97608

Maruszak, A., & Thuret, S. (2014). Why looking at the whole hippocampus is not enough—a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer's disease diagnosis. *Frontiers in cellular neuroscience*, 8, 95. <https://doi.org/10.3389/fncel.2014.00095>

Mattsson, N., Ossenkoppele, R., Smith, R., Strandberg, O., Ohlsson, T., Jögi, J., Palmqvist, S., Stomrud, E., & Hansson, O. (2018). Greater tau load and reduced cortical thickness in APOE ϵ 4-negative Alzheimer's disease: a cohort study. *Alzheimer's research & therapy*, 10(1), 77.

Meramat, A., Rajab, N. F., Shahar, S., & Sharif, R. (2015). Cognitive impairment, genomic instability and trace elements. *The journal of nutrition, health & aging*, 19(1), 48–57.

Moon, S. W., Lee, B., & Choi, Y. C. (2018). Changes in the Hippocampal Volume and Shape in Early-Onset Mild Cognitive Impairment. *Psychiatry investigation*, 15(5), 531–537.

Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997). Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. *Annals of neurology*, 42(1), 85–94.

Mishra, S., Blazey, T. M., Holtzman, D. M., Cruchaga, C., Su, Y., Morris, J. C., Benzinger, T., & Gordon, B. A. (2018). Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ϵ 4 genotype. *Brain : a journal of neurology*, 141(6), 1828–1839.

Morgen, K., Schneider, M., Frölich, L., Tost, H., Plichta, M. M., Kölsch, H., Rakebrandt, F., Rienhoff, O., Jessen, F., Peters, O., Jahn, H., Luckhaus, C., Hüll, M., Gertz, H. J., Schröder, J., Hampel, H., Teipel, S. J., Pantel, J., Heuser, I., Wiltfang, J., ... Meyer-Lindenberg, A. (2015). Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study. *Alzheimer's research & therapy*, 7(1), 27.

Morra, J. H., Tu, Z., Apostolova, L. G., Green, A. E., Avedissian, C., Madsen, S. K., Parikshak, N., Toga, A. W., Jack, C. R., Jr, Schuff, N., Weiner, M. W., Thompson, P. M., & Alzheimer's Disease Neuroimaging Initiative (2009). Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. *NeuroImage*, 45(1 Suppl), S3–S15.

Mueller, S. G., Schuff, N., Raptentsetsang, S., Elman, J., & Weiner, M. W. (2008). Selective effect of Apo e4 on CA3 and dentate in normal aging and Alzheimer's disease using high resolution MRI at 4 T. *NeuroImage*, 42(1), 42–48. <https://doi.org/10.1016/j.neuroimage.2008.04.174>

Mueller, S. G., & Weiner, M. W. (2009). Selective effect of age, Apo e4, and Alzheimer's disease on hippocampal subfields. *Hippocampus*, 19(6), 558–564.

Nao, J., Sun, H., Wang, Q., Ma, S., Zhang, S., Dong, X., Ma, Y., Wang, X., & Zheng, D. (2017). Adverse Effects of the Apolipoprotein E ϵ 4 Allele on Episodic Memory, Task Switching and Gray Matter Volume in Healthy Young Adults. *Frontiers in human neuroscience*, 11, 346.

Novellino, F., López, M. E., Vaccaro, M. G., Miguel, Y., Delgado, M. L., & Maestu, F. (2019). Association Between Hippocampus, Thalamus, and Caudate in Mild Cognitive Impairment APOE ϵ 4 Carriers: A Structural Covariance MRI Study. *Frontiers in neurology*, 10, 1303. <https://doi.org/10.3389/fneur.2019.01303>

O'Dwyer, L., Lamberton, F., Matura, S., Tanner, C., Scheibe, M., Miller, J., Rujescu, D., Prvulovic, D., & Hampel, H. (2012). Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. *PloS one*, 7(11), e48895.

Okonkwo, O. C., Alosco, M. L., Jerskey, B. A., Sweet, L. H., Ott, B. R., Tremont, G., & Alzheimer's Disease Neuroimaging Initiative (2010). Cerebral atrophy, apolipoprotein E varepsilon4, and

rate of decline in everyday function among patients with amnesic mild cognitive impairment. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 6(5), 404–411.

Pennanen, C., Testa, C., Boccardi, M., Laakso, M. P., Hallikainen, M., Helkala, E. L., Hänninen, T., Kivipelto, M., Könönen, M., Nissinen, A., Tervo, S., Vanhanen, M., Vanninen, R., Frisoni, G. B., & Soininen, H. (2006). The effect of apolipoprotein polymorphism on brain in mild cognitive impairment: a voxel-based morphometric study. *Dementia and geriatric cognitive disorders*, 22(1), 60–66.

Poirier, J., Davignon, J., Bouthillier, D., Kogan, S., Bertrand, P., & Gauthier, S. (1993). Apolipoprotein E polymorphism and Alzheimer's disease. *Lancet (London, England)*, 342(8873), 697–699.

Protas, H. D., Chen, K., Langbaum, J. B., Fleisher, A. S., Alexander, G. E., Lee, W., Bandy, D., de Leon, M. J., Mosconi, L., Buckley, S., Truran-Sacrey, D., Schuff, N., Weiner, M. W., Caselli, R. J., & Reiman, E. M. (2013). Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. *JAMA neurology*, 70(3), 320–325.

Qiu, Q., Lin, X., Sun, L., Zhu, M. J., Wang, T., Wang, J. H., Li, G. J., Xiao, S. F., & Li, X. (2019). Cognitive decline is related to high blood glucose levels in older Chinese adults with the ApoE $\epsilon 3/\epsilon 3$ genotype. *Translational neurodegeneration*, 8, 12.

Rane, S., Donahue, M. J., & Claassen, D. O. (2018). Amnesic mild cognitive impairment individuals with dissimilar pathologic origins show common regional vulnerability in the default mode network. *Alzheimer's & dementia (Amsterdam, Netherlands)*, 10, 717–725.

Reiman, E. M., Uecker, A., Caselli, R. J., Lewis, S., Bandy, D., de Leon, M. J., De Santi, S., Convit, A., Osborne, D., Weaver, A., & Thibodeau, S. N. (1998). Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. *Annals of neurology*, 44(2), 288–291.

Reiter, K., Nielson, K. A., Durgerian, S., Woodard, J. L., Smith, J. C., Seidenberg, M., Kelly, D. A., & Rao, S. M. (2017). Five-Year Longitudinal Brain Volume Change in Healthy Elders at Genetic Risk for Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*, 55(4), 1363–1377.

Risacher, S. L., Kim, S., Nho, K., Foroud, T., Shen, L., Petersen, R. C., Jack, C. R., Jr, Beckett, L. A., Aisen, P. S., Koeppe, R. A., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Saykin, A. J., & Alzheimer's Disease Neuroimaging Initiative (ADNI) (2015). APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 11(12), 1417–1429.

Rivan, N., Shahar, S., Rajab, N. F., Singh, D., Che Din, N., Mahadzir, H., Mohamed Sakian, N. I., Ishak, W. S., Abd Rahman, M. H., Mohammed, Z., & You, Y. X. (2020). Incidence and Predictors

of Cognitive Frailty Among Older Adults: A Community-based Longitudinal Study. *International journal of environmental research and public health*, 17(5), 1547.

Rogne, S., Vangberg, T., Eldevik, P., Wikran, G., Mathiesen, E. B., & Schirmer, H. (2016). Magnetic Resonance Volumetry: Prediction of Subjective Memory Complaints and Mild Cognitive Impairment, and Associations with Genetic and Cardiovascular Risk Factors. *Dementia and geriatric cognitive disorders extra*, 6(3), 529–540. <https://doi.org/10.1159/000450885>

Sabuncu, M. R., Buckner, R. L., Smoller, J. W., Lee, P. H., Fischl, B., Sperling, R. A., & Alzheimer's Disease Neuroimaging Initiative (2012). The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. *Cerebral cortex (New York, N.Y. : 1991)*, 22(11), 2653–2661.

Sampedro, F., Vilaplana, E., de Leon, M. J., Alcolea, D., Pegueroles, J., Montal, V., Carmona-Iragui, M., Sala, I., Sánchez-Saudinos, M. B., Antón-Aguirre, S., Morenas-Rodríguez, E., Camacho, V., Falcón, C., Pavía, J., Ros, D., Clarimón, J., Blesa, R., Lleó, A., Fortea, J., & Alzheimer's Disease Neuroimaging Initiative (2015). APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. *Oncotarget*, 6(29), 26663–26674.

Schmidt, H., Schmidt, R., Fazekas, F., Semmler, J., Kapeller, P., Reinhart, B., & Kostner, G. M. (1996). Apolipoprotein E e4 allele in the normal elderly: neuropsychologic and brain MRI correlates. *Clinical genetics*, 50(5), 293–299

Schreiber, S., Schreiber, F., Lockhart, S. N., Horng, A., Bejanin, A., Landau, S. M., Jagust, W. J., & Alzheimer's Disease Neuroimaging Initiative (2017). Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology. *JAMA neurology*, 74(6), 650–659.

Schuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L. M., Trojanowski, J. Q., Thompson, P. M., Jack, C. R., Jr, Weiner, M. W., & Alzheimer's Disease Neuroimaging Initiative (2009). MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. *Brain : a journal of neurology*, 132(Pt 4), 1067–1077. <https://doi.org/10.1093/brain/awp007>

Shahar, S., Lee, L. K., Rajab, N., Lim, C. L., Harun, N. A., Noh, M. F., Mian-Then, S., & Jamal, R. (2013). Association between vitamin A, vitamin E and apolipoprotein E status with mild cognitive impairment among elderly people in low-cost residential areas. *Nutritional neuroscience*, 16(1), 6–12.

Sheline, Y. I., Morris, J. C., Snyder, A. Z., Price, J. L., Yan, Z., D'Angelo, G., Liu, C., Dixit, S., Benzinger, T., Fagan, A., Goate, A., & Mintun, M. A. (2010). APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. *The Journal of neuroscience: the official journal of the Society for Neuroscience*, 30(50), 17035–17040.

Shi, J., Laporé, N., Gutman, B. A., Thompson, P. M., Baxter, L. C., Caselli, R. J., Wang, Y., & Alzheimer's Disease Neuroimaging Initiative (2014). Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimer's disease neuroimaging initiative study. *Human brain mapping*, 35(8), 3903–3918.

Smith, M. Z., Esiri, M. M., Barnetson, L., King, E., & Nagy, Z. (2001). Constructional apraxia in Alzheimer's disease: association with occipital lobe pathology and accelerated cognitive decline. *Dementia and geriatric cognitive disorders*, 12(4), 281–288.

Soldan, A., Pettigrew, C., Lu, Y., Wang, M. C., Selnes, O., Albert, M., Brown, T., Ratnanather, J. T., Younes, L., Miller, M. I., & BIOCARD Research Team (2015). Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease. *Human brain mapping*, 36(7), 2826–2841.

Spampinato, M. V., Rumboldt, Z., Hosker, R. J., Mintzer, J. E., & Alzheimer's Disease Neuroimaging Initiative (2011). Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. *Radiology*, 258(3), 843–852.

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Jr, Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., ... Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 7(3), 280–292.

Stewart, R., Godin, O., Crivello, F., Maillard, P., Mazoyer, B., Tzourio, C., & Dufouil, C. (2011). Longitudinal neuroimaging correlates of subjective memory impairment: 4-year prospective community study. *The British journal of psychiatry : the journal of mental science*, 198(3), 199–205.

Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proceedings of the National Academy of Sciences of the United States of America*, 90(5), 1977–1981.

Strittmatter WJ, Saunders AM, Goedert M, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. *Proc Natl Acad Sci U S A*. 1994;91(23):11183-11186.

Sundermann, E. E., Tran, M., Maki, P. M., & Bondi, M. W. (2018). Sex differences in the association between apolipoprotein E ϵ 4 allele and Alzheimer's disease markers. *Alzheimer's & dementia (Amsterdam, Netherlands)*, 10, 438–447.

Suppiah, S., Didier, M. A., & Vinjamuri, S. (2019). The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer's Disease-Review of Literature and Interesting Images. *Diagnostics (Basel, Switzerland)*, 9(2), 65.

Suri, S., Emir, U., Stagg, C. J., Near, J., Mekle, R., Schubert, F., Zsoldos, E., Mahmood, A., Singh-Manoux, A., Kivimäki, M., Ebmeier, K. P., Mackay, C. E., & Filippini, N. (2017). Effect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex. *NeuroImage*, 152, 509–516.

Tanaka, S., Kawamata, J., Shimohama, S., Akaki, H., Akiguchi, I., Kimura, J., & Ueda, K. (1998). Inferior temporal lobe atrophy and APOE genotypes in Alzheimer's disease. X-ray computed tomography, magnetic resonance imaging and Xe-133 SPECT studies. *Dementia and geriatric cognitive disorders*, 9(2), 90–98.

Tang, X., Holland, D., Dale, A. M., Miller, M. I., & Alzheimer's Disease Neuroimaging Initiative (2015). APOE Affects the Volume and Shape of the Amygdala and the Hippocampus in Mild Cognitive Impairment and Alzheimer's Disease: Age Matters. *Journal of Alzheimer's disease : JAD*, 47(3), 645–660.

Taylor, J. L., Scanlon, B. K., Farrell, M., Hernandez, B., Adamson, M. M., Ashford, J. W., Noda, A., Murphy, G. M., Jr, & Weiner, M. W. (2014). APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years. *Neurobiology of aging*, 35(11), 2479–2485. <https://doi.org/10.1016/j.neurobiolaging.2014.05.011>

Tosun, D., Schuff, N., Truran-Sacrey, D., Shaw, L. M., Trojanowski, J. Q., Aisen, P., Peterson, R., Weiner, M. W., & Alzheimer's Disease Neuroimaging Initiative (2010). Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. *Neurobiology of aging*, 31(8), 1340–1354.

Tosun, D., Schuff, N., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., & Alzheimer's Disease Neuroimaging Initiative (2011). Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data. *Journal of Alzheimer's disease : JAD*, 26 Suppl 3(0 3), 77–90. <https://doi.org/10.3233/JAD-2011-0006>

Utermann G. (1975). Isolation and partial characterization of an arginine-rich apolipoprotein from human plasma very-low-density lipoproteins: apolipoprotein E. *Hoppe-Seyler's Zeitschrift fur physiologische Chemie*, 356(7), 1113–1121.

van Duijn, C. M., de Knijff, P., Wehnert, A., De Voecht, J., Bronzova, J. B., Havekes, L. M., Hofman, A., & Van Broeckhoven, C. (1995). The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. *Annals of neurology*, 37(5), 605–610.

Voevodskaya, O., Sundgren, P. C., Strandberg, O., Zetterberg, H., Minthon, L., Blennow, K., Wahlund, L. O., Westman, E., Hansson, O., & Swedish BioFINDER study group (2016). Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. *Neurology*, 86(19), 1754–1761.

Walsh, B., Slater, S., Nair, B., & Attia, J. (2013). The relationship between the apolipoprotein E e4 allele and hippocampal magnetic resonance imaging volume in community-dwelling individuals with mild Alzheimer's disease. *Degenerative neurological and neuromuscular disease*, 3, 11–14. <https://doi.org/10.2147/DNND.S40835>

Wang, R., Laveskog, A., Laukka, E. J., Kalpouzos, G., Bäckman, L., Fratiglioni, L., & Qiu, C. (2018). MRI load of cerebral microvascular lesions and neurodegeneration, cognitive decline, and dementia. *Neurology*, 91(16), e1487–e1497. <https://doi.org/10.1212/WNL.0000000000006355>

Wang, X., Zhou, W., Ye, T., Lin, X., Zhang, J., & Alzheimer's Disease Neuroimaging Initiative (2019). The Relationship Between Hippocampal Volumes and Delayed Recall Is Modified by APOE ε4 in Mild Cognitive Impairment. *Frontiers in aging neuroscience*, 11, 36.

Wilhelm, J., Frieling, H., von Ahsen, N., Hillemacher, T., Kornhuber, J., & Bleich, S. (2008). Apolipoprotein E polymorphism, homocysteine serum levels and hippocampal volume in patients with alcoholism: an investigation of a gene-environment interaction. *The pharmacogenomics journal*, 8(2), 117–121.

Wolk, D. A., Dickerson, B. C., & Alzheimer's Disease Neuroimaging Initiative (2010). Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, 107(22), 10256–10261.

World Health Organization. (2020). Dementia. Retrieved 16 April 2020, from <https://www.who.int/news-room/fact-sheets/detail/dementia>. 2020.

Wu, L., & Zhao, L. (2016). ApoE2 and Alzheimer's disease: time to take a closer look. *Neural regeneration research*, 11(3), 412–413.

Yokoyama, J. S., Lee, A. K., Takada, L. T., Busovaca, E., Bonham, L. W., Chao, S. Z., Tse, M., He, J., Schwarz, C. G., Carmichael, O. T., Matthews, B. R., Karydas, A., Weiner, M. W., Coppola, G., DeCarli, C. S., Miller, B. L., & Rosen, H. J. (2015). Apolipoprotein ε4 is associated with lower

brain volume in cognitively normal Chinese but not white older adults. PloS one, 10(3), e0118338.

Ystad, M. A., Lundervold, A. J., Wehling, E., Espeseth, T., Rootwelt, H., Westlye, L. T., Andersson, M., Adolfsdottir, S., Geitung, J. T., Fjell, A. M., Reinvang, I., & Lundervold, A. (2009). Hippocampal volumes are important predictors for memory function in elderly women. *BMC medical imaging*, 9, 17.

Zhu, L., Shu, H., Liu, D., Guo, Q., Wang, Z., & Zhang, Z. (2018). Apolipoprotein E ϵ 4 Specifically Modulates the Hippocampus Functional Connectivity Network in Patients With Amnesic Mild Cognitive Impairment. *Frontiers in aging neuroscience*, 10, 289.

Figure 1. PRISMA flowchart of the study selection process

Table 1: MRI Parameters and Measurement Techniques

Table 2. Evidence table of studies included in qualitative synthesis

Table 3 Methodological quality of included studies

Table 4 LOE, according to the 2005 classification system of the Dutch Institute for Healthcare Improvement CBO

Table 5 Strength of Conclusion (modified table)